[go: up one dir, main page]

PL2134371T3 - Koniugaty oligomeru agonisty opioidowego - Google Patents

Koniugaty oligomeru agonisty opioidowego

Info

Publication number
PL2134371T3
PL2134371T3 PL08742082T PL08742082T PL2134371T3 PL 2134371 T3 PL2134371 T3 PL 2134371T3 PL 08742082 T PL08742082 T PL 08742082T PL 08742082 T PL08742082 T PL 08742082T PL 2134371 T3 PL2134371 T3 PL 2134371T3
Authority
PL
Poland
Prior art keywords
oligomer
opioid agonist
agonist conjugates
conjugates
opioid
Prior art date
Application number
PL08742082T
Other languages
English (en)
Inventor
Jennifer Riggs-Sauthier
Bo-Liang Deng
Timothy Andrew Riley
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of PL2134371T3 publication Critical patent/PL2134371T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
PL08742082T 2007-03-12 2008-03-12 Koniugaty oligomeru agonisty opioidowego PL2134371T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90638707P 2007-03-12 2007-03-12
PCT/US2008/003353 WO2008112288A2 (en) 2007-03-12 2008-03-12 Oligomer-opioid agonist conjugates
EP08742082.4A EP2134371B1 (en) 2007-03-12 2008-03-12 Oligomer-opioid agonist conjugates

Publications (1)

Publication Number Publication Date
PL2134371T3 true PL2134371T3 (pl) 2015-06-30

Family

ID=39590911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08742082T PL2134371T3 (pl) 2007-03-12 2008-03-12 Koniugaty oligomeru agonisty opioidowego

Country Status (18)

Country Link
EP (4) EP2620163B1 (pl)
JP (2) JP5420427B2 (pl)
KR (1) KR101568428B1 (pl)
CN (1) CN101646464B (pl)
AU (1) AU2008226822B2 (pl)
CA (1) CA2679479C (pl)
CY (1) CY1117368T1 (pl)
DK (1) DK2134371T3 (pl)
ES (1) ES2534741T3 (pl)
HR (1) HRP20150315T1 (pl)
IL (1) IL200845A (pl)
ME (1) ME02176B (pl)
MX (1) MX2009009851A (pl)
PL (1) PL2134371T3 (pl)
PT (1) PT2134371E (pl)
RS (1) RS53937B1 (pl)
SI (1) SI2134371T1 (pl)
WO (1) WO2008112288A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP3342427A1 (en) * 2008-09-16 2018-07-04 Nektar Therapeutics Pegylated opioids with low potential for abuse
CN105503889B (zh) * 2009-07-21 2019-12-24 尼克塔治疗公司 低聚物-阿片样激动剂轭合物
CA2768392C (en) * 2009-07-21 2018-04-17 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2011088140A1 (en) * 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
US20130022669A1 (en) * 2010-03-30 2013-01-24 Spago Imaging Ab Branched, compact polyethyleneglycol derivatives
ES2446724T3 (es) 2010-11-30 2014-03-10 Blackberry Limited Reselección de células en una red de telecomunicaciones celular
JP6593993B2 (ja) * 2011-11-07 2019-10-23 ネクター セラピューティクス オピオイドアゴニスト化合物と鎮痛性化合物との組成物、剤形、および同時投与
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
EA029512B1 (ru) * 2012-10-30 2018-04-30 Нектар Терапьютикс ТВЕРДАЯ СОЛЕВАЯ ФОРМА α-6-mPEG-O-ГИДРОКСИКОДОНА В КАЧЕСТВЕ ОПИОИДНЫХ АГОНИСТОВ И ЕЕ ПРИМЕНЕНИЯ
JP6577943B2 (ja) 2013-06-28 2019-09-18 ネクター セラピューティクス κオピオイド作動薬及びその使用
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
WO2019113419A1 (en) * 2017-12-08 2019-06-13 The Rockefeller University Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
WO2019189188A1 (ja) 2018-03-29 2019-10-03 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628962A (en) 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US5475019A (en) * 1993-02-08 1995-12-12 East Carolina University Method of treating anxiety-related disorders with 2-aminocycloaliphatic amide compounds
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
MXPA04003597A (es) * 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
GB2399159B (en) 2002-01-11 2005-03-02 Valquest Ltd Flow mixer shuttle
CA2474511C (en) * 2002-02-22 2008-07-22 Bayer Pharmaceuticals Corporation Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
PT1694363E (pt) 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
EP2064215B1 (en) * 2006-09-22 2015-07-15 Zynerba Pharmaceuticals, Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
US20100284960A1 (en) * 2006-11-07 2010-11-11 Nektar Therapeutics Al, Corporation Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist

Also Published As

Publication number Publication date
KR101568428B1 (ko) 2015-11-11
WO2008112288A3 (en) 2008-12-24
IL200845A (en) 2015-08-31
MX2009009851A (es) 2009-09-24
IL200845A0 (en) 2010-05-17
EP2620163A1 (en) 2013-07-31
CA2679479A1 (en) 2008-09-18
RS53937B1 (en) 2015-08-31
EP2620163B1 (en) 2017-05-03
CN101646464B (zh) 2013-05-29
DK2134371T3 (en) 2015-04-27
JP5420427B2 (ja) 2014-02-19
JP5877403B2 (ja) 2016-03-08
KR20090118952A (ko) 2009-11-18
EP3222293B1 (en) 2019-11-27
AU2008226822B2 (en) 2013-08-01
EP2623123A1 (en) 2013-08-07
AU2008226822A1 (en) 2008-09-18
PT2134371E (pt) 2015-04-16
JP2010521466A (ja) 2010-06-24
CA2679479C (en) 2015-10-06
ME02176B (me) 2015-10-20
EP3222293A1 (en) 2017-09-27
WO2008112288A2 (en) 2008-09-18
EP2134371B1 (en) 2015-01-14
EP2134371A2 (en) 2009-12-23
CN101646464A (zh) 2010-02-10
HRP20150315T1 (hr) 2015-04-24
SI2134371T1 (sl) 2015-04-30
JP2013151563A (ja) 2013-08-08
ES2534741T3 (es) 2015-04-28
CY1117368T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
IL200845A0 (en) Oligomer-opoid agonist conjugates
IL211180B (en) Attached polyethylene glycol and docetaxel
IL202616A0 (en) Substituted imidazoheterocycles
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
GB0718224D0 (en) E;ectricalsupply revies
DE602008005470D1 (en) Imidazopyridinone
GB0708226D0 (en) Y-receptor agonists
IL199718A0 (en) Peptide-complement conjugates
IL200965A0 (en) Substituted tetrahydropyrroloquinolines
GB0702547D0 (en) Elevation
GB2439468B (en) NeoGuard
GB0602688D0 (en) Conjugates
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3606P (en) Jaywick xTriticosecale
ZA200702937B (en) Sampler
GB0707851D0 (en) Independent Device
GB0713339D0 (en) Richochet III
GB0713330D0 (en) Richochet III
ZA201000435B (en) Substituted imidazoheterocycles
GB0715691D0 (en) Hair-we-grwo extension
GB0718494D0 (en) MUulti-function extension
GB0703824D0 (en) Hiveometer
GB0704358D0 (en) Filopro
GB0700193D0 (en) Plug-guard
GB0700725D0 (en) Benedicta